SNUS Sonus Pharmaceuticals (MM)

Sonus Pharmaceuticals, Inc. (NASDAQ: SNUS), an oncology drug development company, today announced that Michael A. Martino, President and CEO, will participate in two investor conferences in June 2007: Bear Stearns Boston Biotech Confab, June 7; and the Needham & Company Biotechnology & Medical Technology Conference, being held June 13-14. Bear Stearns Boston Biotech Confab Sonus will be participating in a series of one-on-one meetings, June 7, 2007 Marriott Copley Place, Boston � Needham & Company Sixth Annual Biotechnology & Medical Technology Conference Sonus presentation: Wednesday, June 13, 2007, 11:30 A.M. Eastern Time The New York Palace Hotel, New York Live web cast and archive: www.sonuspharma.com/events.html About Sonus Pharmaceuticals Located near Seattle, Washington, Sonus Pharmaceuticals, Inc. is focused on the development of cancer drugs that are designed to provide better efficacy, safety and tolerability, and are more convenient to use. The Company�s lead product candidate, TOCOSOL� Paclitaxel, is currently in a Phase 3 pivotal trial for the potential treatment of metastatic breast cancer. Adjudicated data from the Phase 3 trial are expected to be available in the third quarter of 2007. TOCOSOL Paclitaxel is an injectable, ready-to-use formulation of paclitaxel that may reduce treatment-limiting side effects and improve anti-tumor activity. In addition to the continuing development of TOCOSOL Paclitaxel, Sonus initiated a Phase 1 clinical trial for its second cancer drug, TOCOSOL Camptothecin, in September 2006. For additional information on Sonus, including past news releases, please visit www.sonuspharma.com. Safe Harbor Certain statements made in this press release are forward-looking such as those, among others, relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products. As discussed in Sonus Pharmaceuticals' filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for 2006 and subsequent Quarterly Reports on Form 10-Q, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others:�the Company's products will require extensive clinical testing and approval by regulatory authorities; such approvals are lengthy and expensive and may never occur; risks that the Company will not be able to complete the Phase 3 clinical trial for TOCOSOL Paclitaxel; risks that clinical studies with TOCOSOL Paclitaxel will be delayed or will not be successful; risks that the FDA may not approve the TOCOSOL Paclitaxel New Drug Application; risks that the Phase 1 clinical trial for TOCOSOL Camptothecin will not be successful; risks of successful development of therapeutic drugs; and risks that the Company may not be successful in obtaining funding from third parties or completing a financing necessary to support the costs and expenses of clinical studies as well as research and development activities. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.